{
    "nct_id": "NCT04607837",
    "official_title": "A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis",
    "inclusion_criteria": "* Diagnosed with Ulcerative Colitis (UC) ≥ 3 months prior to screening\n* Active UC confirmed by endoscopy\n* Moderately active UC defined as a modified Mayo score of 4 to 6 and an endoscopic score ≥ 2 and rectal bleeding score ≥ 1\n* Received a surveillance colonoscopy within 12 months before baseline\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Severe extensive colitis\n* Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease\n* Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis\n* Hospitalization for exacerbation of UC requiring intravenous steroids within 12 weeks prior to or after screening",
    "miscellaneous_criteria": ""
}